Douglas S. Ingram - Nov 3, 2023 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
President & CEO, Director
Signature
/s/ Ryan Brown, as Attorney-in-Fact for Douglas S. Ingram
Stock symbol
SRPT
Transactions as of
Nov 3, 2023
Transactions value $
$2,001,800
Form type
4
Date filed
11/6/2023, 08:00 AM
Previous filing
Jun 1, 2023
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Purchase $792K +10.1K +2.76% $78.57 375K Nov 3, 2023 Direct F1
transaction SRPT Common Stock Purchase $881K +11.1K +2.95% $79.70 386K Nov 3, 2023 Direct F2
transaction SRPT Common Stock Purchase $312K +3.88K +1.01% $80.33 390K Nov 3, 2023 Direct F3
transaction SRPT Common Stock Purchase $16.3K +200 +0.05% $81.26 390K Nov 3, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.03 to $79.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.05 to $80.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.08 to $80.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.